EXONHIT S.A.

ACLARUSDX

Pharmaceutical preparations for treating neurodegenerative diseases and particularly Alzheimer's disease; tests, namely, a blood based biomarker test to identify patients with Alzheimer's disease or at risk of developing the disease and identifying patients responding to specific treatments; biological products and preparations acids for pharmaceutical use, namely, pharmaceutical preparations for the diagnostic of the Alzheimer's disease; capsules sold empty for medicines and diagnostic tests; chemical-pharmaceutical preparations for the diagnosis, the prevention or the treatment of Alzheimer's disease; biopharmaceutical preparations for the diagnosis, the prevention or the treatment of Alzheimer's disease; chemical preparations for medical, pharmaceutical or veterinary use, namely, for diagnosing neurodegenerative diseases and particularly Alzheimer's disease; medical and clinical diagnostic products, namely, probe sets, namely, subset of nucleic acid sequences and nucleic acid libraries, namely, DNA libraries and RNA libraries; nucleic acid sequences for use on biochips, namely, for decoding genes affected by the Alzheimer's disease or revealing the transcriptomic signature of patients affected with Alzheimer's disease; enzymes or enzyme preparations for medical or veterinary use, namely, enzymes stabilizers, namely, enzymes for medical purposes or veterinary use, namely, for treatment of Alzheimer's disease, enzyme substrates, namely, enzymes for medical purposes or veterinary use, namely, for treatment of Alzheimer's disease used as an ingredient in drugs against Alzheimer's disease;Color is not claimed as a feature of the mark.;Chemicals and chemical compositions, namely, nucleic acids attached to a solid support for use in industry and science; analyses, namely, reagent for chemical analyses, namely, quantification of nucleic acid content in laboratories chemical preparations for analyses, other than for medical or veterinary use; biological preparations, namely, quantification of nucleic acid content other than for medical or veterinary use, namely, inoculants, namely, biological microorganisms used in fermentation of silage; chemical preparations for scientific use, other than for medical or veterinary use; chemical preparations or reagents for laboratory, other than for medical or veterinary use; chemical preparations for scientific use, namely, nucleic acid libraries to screen and analyze gene expression, to identify therapeutic targets and products, and to conduct pharmacogenomic and genotoxicity research in the fields of pharmacology, food, chemistry, cosmetology, plant protection, and veterinary sciences; chemical preparations for scientific use, namely, DNA biochips for decoding genes affected by the Alzheimer's disease or revealing the transcriptomic signature of patients affected with Alzheimer's disease, and DNA chips to make visible and analyze gene expression in the fields of human and pharmacological medicine and veterinary science;Medical services; veterinary services; medical assistance services; providing medical information, consultancy and advisory services; hospital services; pharmacists' services relating to the pharmaceutical industry, namely, the filling of and making up prescriptions; health care; telemedicine services;Surgical, medical, dental and veterinary apparatus and instruments, namely, for disease identification, measure of disease severity, measure of disease prognosis, measure of disease progression, measure of disease conversion; medical devices, namely, biochips for analysis of blood; blood testing apparatus; devices, namely, biochips for medical diagnostics uses, namely, biochips for diagnosing Alzheimer's disease, namely, collection kit for blood sampling to perform the test in the right conditions; spoons for administering medicine; receptacles for applying medicines; ultrasound probes for medical use; syringes for medical use; galvanic therapeutic medical devices to diagnose neurodegenerative diseases and particularly Alzheimer's disease;Research and development for third parties in relation to pharmaceutical molecules or biological markers, medicines for the diagnosis and treatment of neurodegenerative diseases; chemical analysis; chemical research; chemical services, namely, analysis of RNA, genes, tissue and blood sample; biotechnology project studies, namely, identifying population of patients affected by the Alzheimer disease and measuring the disease's severity, prognosis, progression and conversion and determining patients sensitivity to treatment; research and development of new products for third parties; biological research; research in biotechnology; technical research in the field of biotechnology; biotechnology analysis services;

ACLARUSDX

The mark consists of the wording ACLARUSDX, with ACLARUS in blue and DX in red.;Pharmaceutical preparations for treating neurodegenerative diseases, particularly Alzheimer's disease; diagnostic reagents and media for medical use, namely, reagents and media for use in testing blood biomarkers, to enable the identification of patients suffering from Alzheimer's disease or at risk of developing the disease and for enabling the identification of patients responding to specific treatments; acidic biological preparations and products for pharmaceutical purposes, namely, pharmaceutical preparations for diagnosing Alzheimer's disease; capsules for diagnostic tests and medicines sold empty; chemico-pharmaceutical preparations for diagnosing, preventing and treating Alzheimer's disease; biopharmaceutical preparations for diagnosing, preventing and treating Alzheimer's disease; chemicals for medical, pharmaceutical or veterinary purposes, namely, chemicals for diagnosing neurodegenerative diseases, especially Alzheimer's disease; medical and clinical diagnosis testing kits comprised of nucleic acid banks, nucleic acids on DNA chips and testing probes; DNA libraries and RNA libraries for medical diagnostic purposes; nucleic acid sequences for use on biochips, for medical and medical diagnostic use, namely, for decoding genes affected by Alzheimer's disease or revealing the transcriptomic signature of patients suffering from Alzheimer's disease; enzymes or enzyme preparations for medical or veterinary purposes, namely, enzyme stabilizers and enzyme substrates used as ingredients in medicines for treatment of Alzheimer's disease; reagents contained in diagnostic test kits for taking blood samples, for the preservation of the biological material under analysis in order to carry out the test under the appropriate conditions;ACLARUS DX;The color(s) red and blue is/are claimed as a feature of the mark.;Chemical preparations and compositions, namely, nucleic acids attached to a solid medium, for industrial and scientific use; chemical fissile preparations for laboratory use; chemical fissile preparations for scientific research; chemical preparations for nucleic acids attached to a solid medium, other than for medical or veterinary purposes; biological preparations, other than for medical or veterinary purposes, namely, blood for enabling the quantification of nucleic acid content; chemicals for scientific use, other than for medical or veterinary purposes; chemical preparations or reagents for laboratory, namely, nucleic acid to screen and analyze gene expression, to identify therapeutic targets and products, and to conduct pharmacogenomic and genotoxicity research in the fields of pharmacology, food, chemistry, cosmetology, plant protection, and veterinary sciences; chemical preparations for scientific use, namely, nucleic acid libraries to screen and analyze gene expression, to identify therapeutic targets and products, and to conduct pharmacogenomic and genotoxicity research in the fields of pharmacology, food, chemistry, cosmetology, plant protection, and veterinary sciences; chemical preparations for scientific use, namely, DNA biochips for decoding genes affected by the Alzheimer's disease or revealing the transcriptomic signature of patients affected with Alzheimer's disease, and DNA chips to make visible and analyze gene expression in the fields of human and pharmacological medicine and veterinary science;Medical services; veterinary services; medical assistance; consulting in the fields of biotechnology and pharmacy, namely, to assist in the selection of Alzheimer's sufferers for clinical trials and to offer personalized treatments; hospitals; pharmacist's services to make up prescriptions; pharmaceutical advice; medical services, namely, facilitating the diagnosis and care of geriatric patients and patients with neurodegenerative diseases; health care; telemedicine services;Surgical, medical, dental and veterinary apparatus and instruments, namely, apparatus and instruments for use in identifying, assessing the seriousness of, assessing the prognoses of, measuring the progression of and measuring the conversion of neurodegenerative diseases such as Alzheimer's; medical apparatus using DNA chips for analyzing blood; apparatus for analyzing blood; apparatus for medical diagnostic purposes, namely, kits for taking blood samples comprising medical instruments for taking blood, DNA chips for diagnosing Alzheimer's disease, and material required for the preservation of the biological material under analysis in order to carry out the test under the appropriate conditions; spoons for medicines; containers specially adapted for the application of medicines, namely, bags and pouches used in the delivery of medication; probes for medical purposes; syringes for medical purposes; galvanic therapeutic devices for diagnosing neurodegenerative diseases, especially Alzheimer's disease;Research and development for others of pharmaceutical molecules or biological markers and medicines for diagnosing and treating neurodegenerative diseases; chemical analyses; chemical research; chemical services, namely, analysis of RNA genes, tissues, and blood samples; biotechnological project studies to identify people suffering from Alzheimer's disease and to measure the seriousness, prognoses, progression and conversion of the disease and to determine how patients respond to treatments; research and development of new products for others; biological research; biotechnological research; technical research in the field of biotechnology; biotechnological analysis services; laboratory analyses, namely, quantification of nucleic acid content for medical and scientific research purposes;